Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Midazolam,Ketamine Hydrochloride,Ondansetron

            Therapeutic Area: Neurology Product Name: MKO Melt

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 03, 2020

            Details:

            Each sublingually administered MKO Melt troche contains 3 mg of midazolam, 25 mg of ketamine, and 2 mg of ondansetron, and is available for institutional purchase through Harrow’s wholly-owned subsidiary, ImprimisRx®.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Amantadine Hydrochloride

            Therapeutic Area: Neurology Product Name: Osmolex ER

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Adamas Pharmaceuticals

            Deal Size: $7.5 million Upfront Cash: Undisclosed

            Deal Type: Agreement December 02, 2020

            Details:

            Under the terms of the agreement, both parties will drop their respective claims relating to the patent litigation, and Adamas will acquire the global rights to OSMOLEX ER for $7.5 million.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tetrahydrocannabinol,Cannabidiol

            Therapeutic Area: Neurology Product Name: Nabiximols

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 13, 2020

            Details:

            Data from three randomized, placebo-controlled trials of nabiximols (GWMS0106, GWSP0604, and SAVANT) conducted were analyzed to assess the relationship between measures of spasticity and muscle strength in lower extremities or walking speed.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bupivacaine,Meloxicam

            Therapeutic Area: Neurology Product Name: Zynrelef

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 13, 2020

            Details:

            The NDA for HTX-011 was resubmitted based on the outcome and final minutes of a Type A End-of-Review meeting with the FDA in September, which was conducted to obtain clarity on the information needed to address the Complete Response Letter (CRL) issued by the FDA in June 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fosphenytoin Sodium

            Therapeutic Area: Neurology Product Name: Sesquient

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 08, 2020

            Details:

            Ready-to-dilute and room temperature stable, SESQUIENT is the only FDA-approved fosphenytoin that allows point-of-care storage, as well as fast and efficient administration in emergency rooms and intensive care units.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Apomorphine Hydrochloride

            Therapeutic Area: Neurology Product Name: Kynmobi

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Marathon Asset Management

            Deal Size: $125.0 million Upfront Cash: $40.0 million

            Deal Type: Agreement November 03, 2020

            Details:

            Marathon will receive all royalties and other payments due under Aquestive’s license agreement with Sunovion Pharmaceuticals as a result of commercialization of KYNMOBI™ sublingual film for acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease.